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Abstract
Background: Phosphodiesterase 7 plays a major role in down-regulation of protein kinase A activity by hydrolyzing cAMP in
many cell types. This cyclic nucleotide plays a key role in signal transduction in a wide variety of cellular responses. In the
brain, cAMP has been implicated in learning, memory processes and other brain functions.
Methodology/Principal Findings: Here we show a novel function of phosphodiesterase 7 inhibition on nigrostriatal
dopaminergic neuronal death. We found that S14, a heterocyclic small molecule inhibitor of phosphodiesterase 7, conferred
significant neuronal protection against different insults both in the human dopaminergic cell line SH-SY5Y and in primary
rat mesencephalic cultures. S14 treatment also reduced microglial activation, protected dopaminergic neurons and
improved motor function in the lipopolysaccharide rat model of Parkinson disease. Finally, S14 neuroprotective effects were
reversed by blocking the cAMP signaling pathways that operate through cAMP-dependent protein kinase A.
Conclusions/Significance: Our findings demonstrate that phosphodiesterase 7 inhibition can protect dopaminergic
neurons against different insults, and they provide support for the therapeutic potential of phosphodiesterase 7 inhibitors
in the treatment of neurodegenerative disorders, particularly Parkinson disease.
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Introduction
Parkinson disease (PD) is one of the most common progressive
neurodegenerative disorder, affecting around 1% of the elderly
population. Typical symptoms of this disease are muscle rigidity,
bradykinesia, resting tremor and postural instability. At the
cellular level, PD is characterized by the loss of dopamine-
containing neurons in the substantia nigra pars compacta (SNpc)
although neuropathology can extend into other brain regions [1].
The cell death leads to the loss of dopamine in areas where these
neurons project, causing the described symptoms. The main
known risk factor is age, however susceptibility genes including a-
synuclein, leucine rich repeat kinase 2 (LRRK-2), and glucocere-
brosidase (GBA) have shown that genetic predisposition is another
important causal factor in a 10% of diagnosed patients. There is
currently no cure and no effective disease-modifying therapy. The
dopamine replacement therapy in clinical use is only palliative;
leading to temporarily limited improvement of clinical symptoms,
and the chronic treatment with dopaminergic drugs have severe
side effects as bradykinesia. Consequently, new approaches to treat
Parkinson disease are needed to find disease’s modifying agents
that may delay or stop the neuronal death.
Neuroinflammation has been increasingly recognized as a
primary mechanism involved in PD pathogenesis [2,3]. Loss of
dopamine-producing neurons in PD is accompanied by
inflammation in surrounding support glial cells. Activation of
microglia has been demonstrated in SN and striatum from
postmortem PD brains and in PD animal models [4,5,6]. This
inflammatory state in glial cells leads to the production of toxic
substances, including cytokines such as IL-1b, IL-6, and TNF-a,
that further damage neurons, leading to a cycle of inflammatory
damage that ultimately worsens the progression of the disease.
New evidence in experimental animals indicates that blocking
the signaling pathways in glial cells responsible for turning
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nergic neurons. Unfortunately, current therapies do not address
this neuroinflammation problem, being focused on ameliorating
the symptoms of dopamine loss rather than on the underlying
causes of injury to dopaminergic neurons. Targeting the
signaling pathways in glial cells responsible for neuroinflamma-
tion represents a promising new therapeutic approach designed
to preserve remaining neurons in PD patients, thereby
extending the window of efficacy of existing symptomatic drugs
in order to better maintain quality of life. Given the evidence for
neuroinflammation in PD, agents with anti-inflammatory
effects have been investigated for their neuroprotective
potential [7].
Different studies have suggested that cyclic AMP (cAMP) levels
might play an important role in neuroprotection and in the
neuroinflammatory response [8,9] thus control of the levels of this
nucleotide could trigger the regulation of the pathological
neuroinflammatory process and, consequently, to delay the
progression of neurodegenerative disorders, such as PD. Intracel-
lular cAMP levels depend on one hand on their synthesis by
adenylyl cyclases and, on the other hand, on its degradation by
cyclic nucleotide 39,5 9-phosphodiesterases (PDEs) [10,11]. Hence,
PDEs have recently emerged as important drug targets for
regulating several diseases [12].
The PDEs comprise a family of 21 members, which have been
so far classified into 11 groups, according to their sequence
homology, cellular distribution, and sensitivity to different PDE
inhibitors [11,12], being some of them expressed on central
nervous system [13]. PDE7 is a cAMP-specific PDE, which is
insensitive to a PDE4 inhibitor, Rolipram [10,11] and it has been
recently demonstrated that can be a target for the control of
neuroinflammation [14]. The PDE7 family is composed of two
genes, PDE7A and PDE7B. High mRNA concentrations of both
PDE7A and PDE7B are expressed in rat brain and in numerous
peripheral tissues, although the distribution of these enzymes at
the protein levels has not been reported. Within the brain PDE7A
mRNA is abundant in the olfactory bulb, hippocampus, and
several brain-stem nuclei [15]. The highest concentrations of
PDE7B transcripts in the brain are found in the cerebellum,
dentate gyrus of the hippocampus and striatum [16,17]. There is
very little information regarding the physiological functions
regulated by PDE7. It has been shown that PDE7 is involved in
pro-inflammatory processes and is necessary for the induction of
T-cell proliferation [18]. In addition, specific inhibitors of PDE7
have been recently reported as potential new drugs for the
treatment of brain diseases [19]. However, a detailed analysis of
the effect of these compounds on normal central nervous system
function as well as in pathological conditions have yet to be
described.
Several years ago, our research group was the first one in
reporting the first PDE7 selective inhibitors [20]. Since then, a lot
of efforts have been done to increase potency and selectivity of this
kind of compounds, conforming a great variety of diverse chemical
compounds with interesting pharmacological profiles [21]. We
have recently reported a new and diverse chemical family of PDE7
inhibitors, the quinazolines ones, discovered by using a ligand-
based virtual screening [22]. Moreover, the biological profile of
these new thioxoquinazolines showed that they are useful
compounds to decrease the inflammatory activation in a T-cell
line [23].
In the present study, we demonstrate for the first time, that
PDE7 inhibition enhances neuroprotection and diminishes
neuroinflammation in well-characterized cellular and animal
models of PD. In addition, treatment of adult rats with the blood
brain barrier permeable PDE7 inhibitor named S14 (Phenyl-2-
thioxo-(1H)-quinazolin-4-one, Figure 1) significantly protects
dopaminergic neurodegeneration and improves motor function
in LPS-lesioned animals. Lastly, we also show that its effects are
mediated by the cAMP/PKA signaling pathway. As such, these
findings identify PDE7 as a potential therapeutic target for the
treatment of Parkinson Disease.
Results
Expression of PDE7
We first analyzed whether PDE7 was expressed throughout the
central nervous system of the adult rat. As can be seen in
Figure 2A, significant levels of PDE7A and PDE7B were detected
in different brain regions including the striatum. In the case of the
SNpc, we found, by immunohistochemistry studies, that the levels
of PDE7A and PDE7B are low in the basal state. However, they
were notably increased after LPS injection (Figure 2B). These
results are of interest since these genes have been related to
inflammation [18]. Moreover, the increased observed after LPS
injury support our data showing an important role for PDE7
inhibitors as neuroprotective agents of dopaminergic neurons.
Additionally, both isoforms of PDE7 are expressed in the SH-
SY5Y neuroblastoma cell line and in primary rat mesencephalic
cultures (Fig. 2C). Besides, double immunocytochemistry studies
clearly show that TH positive cells expressed PDE7A and
PDE7B.
PDE7 inhibition protects neuronal SH-SY5Y cells from 6-
hydroxydopamine (6-OHDA)-induced death
The human dopaminergic neuronal cell line SH-SY5Y
possesses many qualities of substantia nigra neurons [24] and is
therefore widely used as a model to study the death of
dopaminergic neurons. Since S14 has been described as a PDE7
inhibitor, we first analyzed whether this compound could increase
cAMP levels on SH-SY5Y cells. To this end, cells were treated for
1 h with S14 and two well-known PDE4 and PDE7 inhibitors,
Rolipram and BRL50481, respectively, and cAMP levels were
analyzed by ELISA. Figure 3A shows that, as expected, Rolipram
and BRL50481, were able to elevate the levels of cAMP in these
cultures. Treatment with S14 also resulted in a significant increase
in the levels of cAMP. We next analyzed the phosphorylation state
Figure 1. Structure of the PDE7 inhibitor used in the
experiments, the quinazoline derivative S14.
doi:10.1371/journal.pone.0017240.g001
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the cAMP/PKA signaling pathway. As shown in Figure 3B,
treatment of SH-SY5Y with Rolipram, BRL50481 or S14,
together with 6-OHDA, resulted in an increase of phosphorylated
CREB levels.
We then examined the effect of S14 on the cell death induced
by 6-OHDA exposure. As shown in Figure 3C, 6-OHDA
treatment resulted in a loss of viability, as assessed by a decline
in (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
(MTT) and a significant elevation in lactate dehydrogenase (LDH)
level (Fig. 3C), as compared with control untreated cells.
Incubation with the PDE7 inhibitor quinazoline compound S14
afforded significant protection against 6-OHDA-induced cell
death lowering elevated LDH levels by as much as 50% and
reversing the decline in MTT by 22%. This neuroprotective effect
was mimicked by BRL50481 and by Rolipram. S14 has an IC50
of 5.5 mM on PDE7A, five times more potent than its inhibition on
PDE4D (IC50=22 mM) [22]. Quinazoline derivative S14 does
not inhibit PDE3 (3% of inhibition at 10 mM) therefore preventing
the compound from possible cardio toxic effects. Hence, the results
obtained here suggest that S14 protects the human dopaminergic
neuronal cell line SH-SY5Y from cell death through an inhibition
of the PDE7 enzyme.
Toxicity induced by 6-OHDA was also accompanied by an
increase in nitrite production (Fig. 3C, lower panel), and its
concentration was brought toward normality after S14 treatment,
indicating that this drug blocks 6-OHDA-induced oxidative stress,
which leads to free radical generation.
Activation of PKA by cAMP is required for S14-induced
neuroprotection of SH-SY5Y
The most common intracellular target of cAMP is PKA. PKA
activation is responsible for many of the actions attributed to
cAMP [25]. Nonetheless there are other effects of this nucleotide,
which are not mediated by PKA [26,27]. We therefore
investigated if PKA activation is required for the neuroprotective
actions of S14. To this end, SH-SY5Y exposed to 6-OHDA and
pretreated or not with Rolipram, BRL50481 or S14, were treated
with the PKA inhibitor H89 or the specific membrane-permeable
inhibitor of PKA activation adenosine 39,59-cyclic monopho-
sphorothioate Rp-isomer (Rp-cAMP). As shown in Figure 3C,
both compounds prevented the increase in cell viability and the
decrease in nitrite liberation elicited by the three PDE inhibitors,
suggesting that the cAMP/PKA pathway mediates their effects on
SH-SY5Y cells.
Lastly, apoptosis was determined by measuring the levels of
active caspase 3 and Annexin V analysis (Fig. 3D). Our results
indicate that 27% of the SH-SY5Y cell population was positive
for caspase 3 staining within 16 h after treatment with 6-OHDA
and that this effect was almost completely reversed by the
treatment with the S14 compound. Annexin V-FITC analysis
also showed a significant decrease in the number of apoptotic
cells in those cultures treated with S14 (Fig. 3D). These results
suggest that S14 is rescuing SH-SY5Y cells from 6-OHDA-
induced apoptosis.
PDE7 inhibition protects cultured primary mesencephalic
cells from lipopolysaccharide- and 6-OHDA-induced cell
death
We next examined whether PDE7 inhibition could also have
neuroprotective effects on primary ventral mesencephalic cultures.
These cultures are known to be vulnerable to LPS treatment,
resulting in a loss of neuronal viability [28]. The viability of
mesencephalic cell cultures, known to be rich in dopaminergic
neurons, was determined by quantifying tyrosine hydroxylase (TH)
immunoreactivity after exposure to LPS. Treatment with this
endotoxin decreased the number of TH
+ cells by 42% (Fig. 4A).
S14 addition significantly preserved TH
+ cells from LPS toxicity.
No significant difference in the number of DAPI-positive nuclei
was found among the treated cultures (data not shown). We also
analyzed whether S14 affected the LPS-induced expression of
TNF-a and COX-2, two well known proinflammatory agents. As
shown in Figure 4A, incubation of primary mesencephalic cultures
with S14 completely abrogated the induction of TNF-a and COX-
2 expression after LPS treatment, suggesting that the protection
observed by S14 could be exerted, at least in part, through an
effect upon inflammatory reaction of microglial cells present in the
cultures. These results were further corroborated by measuring
nitrite liberation to the culture medium (Fig. 4B). LPS treatment
resulted in an increase in the concentration of nitrites in the
cultures medium, which was significantly prevented by S14. In fact
the levels of nitrites in the S14-treated cultures were even lower
that those detected in control non-treated cells.
The neuroprotective effects of S14 were also tested after
exposure to the dopaminergic toxin 6-OHDA. As expected, 6-
OHDA significantly decreased TH-positive cells (80%) (Fig. 4C).
Addition of S14 to the cultures conferred a robust protection
against 6-OHDA-mediated cell loss.
Neuroprotective role of PDE7 inhibition in an in vivo
model of PD
Given the in vitro anti-inflammatory and neuroprotective effects
described above, we then assessed the efficacy of S14 in a well-
characterized rodent model of PD. LPS injection into the SNpc of
rodents induces dopaminergic cell loss and microglial activation
[29,30]. To this end, adult rats were injected unilaterally in the
SNpc with vehicle, LPS, or LPS plus S14 and were killed 72 h
after injection. Histological analysis were used to evaluate the
extend of dopaminergic cell loss and microglial activation in the
SNpc of the different groups of animals. A significant preservation
of dopaminergic neurons was found in S14-injected rats compared
with abundant dopaminergic neuron damage after injection with
LPS (Fig. 5). Quantitative studies showed a decrease of 85%,
compared with the vehicle-injected rats, in the number of
dopaminergic neurons in the SNpc after LPS injection. In
contrast, in the S14-treated group, only a moderate decrease
(25%) in dopaminergic cell number was observed 3 days after LPS
injection. These results extend the observations made in vitro and
suggest that treatment of LPS-injected animals with S14 results in
an almost complete prevention of dopaminergic injury. In
addition, we also analyzed the effect of BRL50481, a well
Figure 2. Western blot and immunocytochemical analysis of PDE7A and PDE7B. (A) Representative Western blot and quantification
analysis showing expression levels of PDE7A and PDE7B in different brain regions and in the dopaminergic cell line SH-SY5Y. Cx, cerebral cortex; Hip,
hippocampus; St, striatum. (B) Inmunohistochemical analysis of PDE7A and PDE7B expression in the substantia nigra pars compacta (SNpc) of adult
rats. Figure also shows the expression of both isoenzymes 72 h after lipopolysaccharide (LPS, 10 mg) injection in this area. Scale bar, 25 mm. (C)
Immunofluorescence analysis of PDE7A and PDE7B expression (green) and tyrosine hydroxylase (TH, red) in the dopaminergic cell line SH-SY5Y and in
primary mesencephalic cultures. Representative results of at least three independent experiments are shown. Scale bar, 10 mm. Nuclei were
counterstained with DAPI (blue).
doi:10.1371/journal.pone.0017240.g002
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results showed that BRL50481 has similar neuroprotective and
anti-inflammatory effects as S14. Only a 20% decrease in the
number of dopaminergic neurons (Figure 5B) was observed in rats
injected with this compound, compared to 85% found in LPS-
treated animals.
One of the events that take place in the SNpc after LPS injury is
the activation of microglial cells, which is in part responsible for
the dopaminergic cell degeneration. Microglial cells (identified as
OX-42-positive cells) were very scarce in the contralateral part of
LPS-injected animals and in the SNpc of vehicle-injected animals
(Figure 6A). Seventy-two hours after LPS injection, a high OX-42
immunoreactive signal was clearly observed in the SNpc. This
strong microgliosis was completely absent in the animals treated
with the quinazoline PDE7 inhibitor S14. Also, BRL50481
treatment of LPS-injured rats completely abrogated the micro-
gliosis observed in the LPS-treated group (Figure 6A). Altogether,
these results reinforce our hypothesis that PDE7 could be an
important target for neuroprotection of dopaminergic neurons.
Finally we analyzed the effects of S14 treatment on rotational
behavior by assessing the behavioral changes in hemi-parkinsonian
rats. To this end, three weeks following LPS lesion rats were
injected with apomorphine, which is known to induce contralat-
eral rotational behavior in denervated animals. Figure 6B shows
that the LPS-treated rats exhibited 7 contralateral turns per
minute following an administration of apomorphine. Rats lesioned
with LPS and treated with S14 showed a significant improvement
(only 1 turn per minute) after apomorphine. Vehicle-treated
animals showed no contralateral rotational behavior. Immunohis-
tochemistry analysis also showed that, three weeks after LPS
administration, dopaminergic cell death was significantly attenu-
ated in the group treated with S14 (data not shown).
Discussion
In this study, we have demonstrated, for the first time, that
inhibition of PDE7 induces neuroprotection of human dopami-
nergic neuronal cells SH-SY5Y and of primary mesencephalic
cultures and attenuates the production of nitrites and proin-
flammatory agents. Our data also show that inhibition of PDE7
results in an inhibition of microglial activation and has
neuroprotective effects on the nigrostriatal system in an in vivo
model of PD. In addition, the neuroprotective effect of PDE7
inhibition appears to be mediated by the cAMP/PKA signaling
pathway. These results suggest that inhibition of PDE7 can
represent a new therapeutic approach for the treatment of PD and
other neurodegenerative disorders in which inflammation pro-
cesses are involved. Thus, PDE7 inhibitors may represent a new
generation of valuable drugs.
We initially analyzed the neuroprotective and anti-inflammato-
ry effects of the PDE7 inhibitor S14 in the human dopaminergic
cell line SH-SY5Y and in primary mesencephalic cultures. Human
neuroblastoma cells exposed to 6-OHDA are used as in vitro model
for PD, due to similar cellular processes that occur in the
degenerating dopaminergic neurons [31]. We show that S14
significantly attenuates 6-OHDA-induced neuronal cell death and
nitrite liberation in the SH-SY5Y neuronal cell line and in
mesencephalic cultures. These effects are accompanied by an
elevation of intracellular cAMP levels, indicating that also in
dopaminergic neurons the activity of PDE7 is important in
governing cellular cAMP concentration. The mechanism of action
of this compound seems to be the inhibition of the PDE7 enzyme,
the subsequent activation of the cAMP/PKA signaling pathway
and the activation of the transcription factor cAMP response
element-binding protein (CREB) by phosphorylation. It is known
that cAMP can activate at least three different signaling pathways
within cells. The first one to be characterized and the most
extensively studied rely on the activation of PKA, which then
phosphorylates different substrates including transcription factors
such as CREB. However, cAMP can also stimulate the guanine
nucleotide exchange protein Epac, which in turn activates the
GTPase Rap-1 [32]. Other pathway identified as activated by
cAMP includes another guanine nucleotide exchange protein
called CNrasGEF, which directly activates Ras [33]. Yet, our
results showing a reversion of the anti-inflammatory and
neuroprotective effects of S14 by both Rp-cAMP and H89 (a
specific inhibitor of PKA activation), support the notion that S14
specifically activates cAMP-dependent PKA activation.
These neuroprotective actions of PDE7 inhibition are in
accordance with previous findings showing that cAMP signaling
pathway might inhibit cell death in various neurodegenerative
disorders. Previous work has demonstrated a clear involvement of
PKA in neuroprotection [34,35]. Absence of CREB in developing
brain results in generalized cell death, whereas postnatal
disruption of this transcription factor triggers progressive neuro-
degeneration [36]. Also, it has been shown that CREB is necessary
for neuronal survival and axonal growth in different neuronal
populations [9]. Of note, inhibition of cAMP signaling pathway
has been suggested to contribute to Hungtinton disease pathology
[37,38,39]. Our results add new and important data establishing
that elevation of intracellular cAMP levels through inhibition of
PDE7 promotes protection of dopaminergic cells and has potent
anti-inflammatory effects.
To evaluate the translational relevance of the aforementioned
cellular effects, the anti-inflammatory and neuroprotective actions
of direct administration of S14 into the brain were assessed in a
classical rodent model of PD. Research in the last years has
unveiled an important role for neuroinflammation in the
degeneration of the nigrostriatal dopaminergic pathway that
constitutes the pathological basis of PD. Neuroinflammation is
characterized by the activation of glial cells that release various
cytotoxic substances, including pro-inflammatory cytokines, reac-
Figure 3. Effect of S14 on 6-OHDA-induced SH-SY5Y cell death. Cells were treated with Rolipram (30 mM), BRL50481 (BRL, 30 mM), or S14
(10 mM) as indicated in Methods. (A) Intracellular levels of cAMP in cells treated during 1 hr with the indicated compounds.
**p,0.01;
***p,0.001
versus non-treated (basal) cells. (B) Representative Western blot showing phosphorylation of CREB after incubation of cells with 6-OHDA (35 mM) for
16 h in the presence or absence of the indicated compounds. A specific anti-phospho-CREB antibody was used. The use of an antiserum that does
not discriminate between CREB and phospho-CREB (bottom panel) indicates that the total levels of CREB are not affected by the treatments.
Quantification analysis are shown.
***p,0.001 versus non-treated (basal) cells;
#p,0.05,
##p,0.01,
###p,0.001 versus 6-OHDA-treated cells. Rol,
Rolipram (C) Cell viability, cytotoxicity and nitrite production were measured as indicated in Methods. Some cultures were pretreated with the
protein kinase A inhibitor H89 or the cAMP antagonist Rp-cAMP. Values represent the mean 6 SD of six replications in three different experiments.
**p,0.01;
***p,0.001, versus 6-OHDA-treated cells;
##p,0.01,
###p,0.001 versus the values obtained in the absence of H89 or Rp-cAMP (D)
Apoptotic levels were determined by active caspase 3 (green) and Annexin V-FITC (green) immunodetection. Representative images of at least three
independent experiments are shown. Scale bar, 10 mm. Nuclei were counterstained with DAPI (blue). Quantification of active caspase 3 and Annexin
V-FITC-positive cells is shown.
***p,0.001 versus 6-OHDA-treated cells.
doi:10.1371/journal.pone.0017240.g003
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17240Figure 4. Effect of S14 on cell death and inflammation processes in mesencephalic cell cultures induced by incubation with LPS or
6-OHDA. (A) Rat primary mesencephalic cultures were treated with LPS (1 mg/ml) in the absence or presence of S14 (10 mM) and the expression of
TH, COX-2 and TNF-a was evaluated by immunofluorescence analysis using specific antibodies, as described in Methods. Representative results of
three independent experiments are shown. Scale bars, 20 mm. Nuclei were counterstained with DAPI. Quantification of the numbers of
immunoreactive cells was performed as described in Methods. Values represent the mean from three different experiments and twenty independent
fields ($50 cells/field) per culture.
*p,0.05;
***p,0.001 versus LPS-treated cells. (B) Nitrite production was evaluated by the Griess reaction. Values
represent the mean 6 SD of six replications in three different experiments.
***p,0.001, versus LPS-treated cells (C) Rat primary mesencephalic
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microglia is implicated in the pathology of many neurodegener-
ative disorders [40]. Inhibition of this process could then protect
against neurodegeneration and expansion of brain injury. This
view is further supported by epidemiologic data showing that long-
term treatment with non-steroidal anti-inflammatory drugs may
protect against Alzheimer disease and Parkinson disease
[41,42,43]. Administration of the bacterial endotoxin LPS in rats
induces a consistent glial activation and a subsequent dopaminer-
gic cell loss that parallels many aspects of PD [29,44,45]. Here, we
show that S14 has potent anti-inflammatory effects in vivo after
LPS injection in the SNpc. Our results indicate that this
compound significantly reduces the accumulation of reactive
microglia in the striatum of lesioned-rats. The underlying
mechanism of this anti-inflammatory effect of S14 may involve
the suppression of certain cytokines, e.g. TNF-a. Indeed our in vitro
results show that treatment of primary mesencephalic cultures with
S14 significantly decreased TNF-a and COX-2 levels, two potent
pro-inflammatory agents.
Besides this potent anti-inflammatory action of S14, the
administration of this compound also causes a significant
preservation of dopaminergic cells loss in the SNpc. PD is
characterized by selective degeneration of dopaminergic neurons
in the SN. Rats receiving LPS presented classic reductions in the
number of TH-immunoreactive cells, a marker of dopaminergic
cells in the SN. These animals also demonstrated motor function
deficits. A unilateral lesion in nigrostriatal dopaminergic pathway
produces an imbalance of dopamine between the lesioned and
unlesioned striatum leading to circle toward the side of the lesion
[46,47]. Treatment of the animals with a dopamine agonist such
as apomorphine leads to contralateral rotational behavior in
denervated animals [48]. This rotational behavior is consistent
with damage to dopaminergic neurons in the SN and the decrease
of dopamine in the striatum [49]. Behavioral assessment detected
significant differences between the LPS and control animals at 3
weeks after LPS administration. S14 administration provided
complete protection, as assessed by TH-positive cell number and
motor behavioral. We found that apomorphine-induced turning
behavior in the LPS-treated group was significantly inhibited by
S14 treatment. Overall, the LPS rats treated with S14 were
indistinguishable from controls.
In conclusion, here we have shown that inhibition of PDE7
hinders dopaminergic cell death and glial activation in an animal
model of PD. The mechanisms that underlie these effects appear
to be an elevation of intracellular cAMP, which acts via the PKA-
CREB pathway. These results show for the first time that
inhibition of the PDE7 enzyme leads to dopaminergic neuronal
protection and therefore its inhibitors may exert useful therapeutic
actions in patients with PD, a hypothesis that is amenable to
clinical testing.
Materials and Methods
Animal experiments
All procedures with animals were specifically approved by the
‘Ethics Committee for Animal Experimentation’ of the Instituto de
Investigaciones Biomedicas (CSIC-UAM), licence number SAF
2010/16365, and carried out in accordance with the protocols
issued which followed National (normative 1201/2005) and
International recommendations (normative 86/609 from the
European Communities Council). Adequate measures were taken
to minimize pain or discomfort of animals.
LPS injection in vivo
Adult male Wistar rats (8–12 weeks old) were used in this study.
The animals, divided into four groups, with at least six rats in each
group, were properly anaesthetized and placed in a stereotaxic
apparatus (Kopf Instruments, CA). LPS (10 mg in 2.5 ml PBS)
alone or in combination with S14 (20 nmol) or with BRL50481
(60 nmol) were injected into the right side of the SNpc
(coordinates from Bregma: posterior - 4.8 mm; lateral +
2.0 mm; ventral: +8.2 mm, according to the atlas of Paxinos
and Watson [50]). The dose of LPS was chosen based in previous
published data [29,30,51]. The amount of S14 injected was
calculated taking into account the distribution volume of this
cerebral area and the effective dose observed in the in vitro
experiments. Control animals of the same age were injected with
PBS. Rats were then housed individually to recover and sacrificed
72 h after lesioning.
Histology and Immunohistochemistry
Seventy-two hours after lesioning, the animals were anaesthe-
tized and perfused transcardially with a 4% paraformaldehyde
solution. The brains were removed, postfixed in the same solution
at 4uC overnight, cryoprotected, frozen, and 30 mm coronal
sections were obtained in a cryostat. Free-floating sections were
processed for cresyl violet (Nissl stain) or immunohistochemistry
using the diaminobenzidine method as previously described [52].
To detect PDE7 in SNpc, rabbit anti-PDE7A and goat anti-
PDE7B antibodies (Santa Cruz Biotech) were used. For immuno-
detection of activated glia and dopaminergic neurons, a mouse
anti-CD11b antibody (Serotec, Germany) and a rabbit anti-
tyrosine hydroxylase (Chemicon/Millipore, USA) antibody, re-
spectively, were used. After being dehydrated, cleared, and
mounted with DePeX (Serva, Heidelberg, Germany), samples
were examined with a Zeiss (Oberkochen, Germany) Axiophot
microscope, equipped with an Olympus DP-50 digital camera,
and a Leica (Nussloch, Germany) MZ6 modular stereomicroscope.
Four animals from each experimental group were analyzed.
Neuronal integrity and specifically dopaminergic cell death was
assessed by counting the percentage of Nissl-stained and TH
+ cells,
respectively, in the SNpc in four well-defined high magnification
(x400) fields per animal, using a computer-assisted image analySIS
software (Soft Imaging System Corp). Microgliosis was quantified
similarly.
Behavioural testing. Apomorphine-induced rotational
behavioural test was performed 3 weeks following LPS lesioning
of the SNpc. Rats were given a subcutaneous injection of
apomorphine (0.5 mg/kg in saline), then placed individually in
plastic beakers and videotaped for 30 minutes. Analysis of
completed (360u) rotations was made offline and expressed as
number of turns per minute. Rats showing more than six turns per
minute were considered as properly lesioned. Three different
experiments with al least 12 animals/experimental group were
performed.
cultures were treated with 6-OHDA in the absence or presence of S14 and the expression of TH
+ cells was evaluated by immunofluorescence analysis
using specific antibodies, as described in Methods. Representative results of three independent experiments are shown. Scale bars, 20 mm. Nuclei
were counterstained with DAPI. Quantification of the numbers of immunoreactive cells was performed as described in Methods. Values represent the
mean 6 SD from three different experiments and twenty independent fields ($50 cells/field) per culture.
***p,0.001 versus 6-OHDA-treated cells.
doi:10.1371/journal.pone.0017240.g004
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Cultures were derived from the ventral mesencephalon of rat
embryos at embryonic day 14. Briefly, rats were killed by cervical
dislocation and embryonic sacs dissected and collected in ice-cold
HBSS medium (Ca
2+ and Mg
2+ free). Ventral mesencephalon was
isolated, gently minced and triturated with a micropipette in HBSS
medium. Then the supernatant was collected, and centrifuged at
1200 xg/5 min. The pellet was resuspended in culture media (MEM
supplemented with 10% FBS, 10% HS, glucose 1 g/l glutamine
2 mM, sodium pyruvate 1 mM, non-essential aminoacids 100 mM,
penicillin 50 U/ml and streptomycin 50 mg/ml), and cells seeded
onto 24-well plates (5610
5 cells/well) or 96-well plates (1610
5 cells/
well). After 1 week in culture, cells were treated with LPS (1 mg/ml)
[53,54,55] or 6-OHDA (35 mM, Sigma), alone or in combination
with S14 (10 mM). The effective dose of S14 was determined based
on previous studies on EC50 [22]. After 24 h, cultures were
processed for immunocytochemistry and nitrite determination.
SH-SY5Y cell culture
The human neuroblastoma SH-SY5Y cell line was obtained
from Sigma-Aldrich and propagated in F12 medium/EMEM
containing glutamine (2 mM), 1% of non-essential amino acids
and 15% of fetal bovine serum (FBS), under humidified 5% CO2
and 95% air. On attaining semiconfluence, cells were treated or
not with 6-OHDA (35 mM, Sigma) for 24 h. Some cultures were
pretreated for 1 h with S14 (10 mM), Rolipram (30 mM, Tocris
Bioscience) or BRL-50481 (30 mM, Tocris Bioscience). To analyze
the role of cAMP, some plates were also preincubated with the
PKA inhibitor H-89 (20 mM, BIOMOL Research Laboratories) or
the cAMP antagonist Rp-cAMP (100 mM, BIOMOL Research
Laboratories) for 24 h before the addition of the different
compounds. At different times after treatments, cells were
processed for western blot, cell viability assay, LDH measurement,
nitrites release, and immunocytochemical analysis.
Cell viability assay
Cell viability was measured using the MTT assay (Roche
Diagnostic, GmbH), based on the ability of viable cells to reduce
yellow MTT to blue formazan. Briefly, cells were cultured in 96-
well plates and treated with the indicated compounds for 16 h, then
cells were incubated with MTT (0.5 mg/ml, 4 h) and subsequently
solubilized in 10% SDS/0.01 M HCl for 12 h in the dark. The
extent of reduction of MTT was quantified by absorbance
measurement at 595 nm according to the manufacturer’s protocol.
LDH release assay
Cytotoxicity was assessed by measuring the levels of lactate
dehydrogenase (LDH) released into the culture medium 16 h after
the different treatments. LDH activity was measured using a
Cytotoxicity Detection kit (Roche Molecular Biochemicals, Indianap-
olis, IN, USA) and quantified by measuring absorbance at 490 nm.
Nitrites measurement
Accumulation of nitrites in media was assayed by the standard
Griess reaction. After stimulation of cells with the different
treatments for 16 hours, supernatants were collected and mixed
with an equal volume of Griess reagent (Sigma- Aldrich). Samples
were then incubated at room temperature for 15 minutes and
absorbance read using a plate reader at 492/540 nm.
cAMP assay
Quantification of cAMP was carried out using the EIA (enzyme
immunoassay) kit from GE Healthcare. Briefly, SH-SY5Y cells
were seeded at 3610
4/well in 96-well dishes and incubated
overnight before the assay. After 1 h incubation with S14,
Rolipram or BRL50481, cAMP intracellular levels were deter-
mined following the manufacture’s instructions.
Immunoblot analysis
Proteins were isolated from brain tissue or cell cultures by
standard methods. Some SH-SY5Y cultures were pre-treated with
Rolipram (30 mM), BRL50481 (BRL, 30 mM), or S14 (10 mM) for
1 h before 6-OHDA (35 mM) addition and kept in these conditions
for 16 h. A total amount of 30 mg of protein was loaded on a 10%
SDS-PAGE gel. After electrophoresis, proteins were transferred to
nitrocellulose membranes (Protran, Whatman, Dassel, Germany)
and blots were probed with the indicated primary antibodies, as
previously described [56]. The antibodies used were the following:
rabbit anti-PDE7A (1:1000, Santa Cruz Biotech., USA), goat anti-
PDE7B (1:1000; Santa Cruz Biotech., USA), mouse monoclonal
anti-a-tubulin (1:5000; Sigma), rabbit anti-p-CREB (1:1000; Cell
Signaling) and rabbit anti-CREB (1:1000; Cell Signaling). All
incubations with primary antibodies were carried out overnight,
with gently shaking at 4uC. Secondary peroxidase-conjugated
donkey anti-rabbit and rabbit anti-mouse antibodies were from
Amersham Biosciences (GE Healthcare, Buckinghamshire, En-
gland) and Jackson Immunoresearch, respectively. Secondary
antibodies incubations were done at room temperature for 1 hour.
Values in figures are the average of the quantification of at least
three independent experiments corresponding to three different
samples.
Immunocytochemistry
At the end of the treatment period, SH-SY5Y or primary
mesencephalic cultures, grown on glass cover-slips in 24-well cell
culture plates, were washed with PBS and fixed for 30 min with
4% paraformaldehyde at 25uC and permeabilized with 0.1%
Triton X-100 for 30 min at 37uC. After 1 h incubation with the
corresponding primary antibody, cells were washed with PBS and
incubated with an Alexa-labeled secondary antibody (Invitrogen,
San Diego, CA) for 45 min at 37uC. Images were acquired using a
Radiance 2100 confocal microscope (Bio-Rad, Hercules, CA),
with a 350 nm diode laser to excite DAPI (4,6,diamidino-2-
phenylindole) a 488-Argon laser to excite Alexa 488 and a 647
laser to excite Alexa 647. Confocal microscope settings were
adjusted to produce the optimum signal-to-noise ratio. To
compare fluorescence signals from different preparations, settings
were fixed for all samples within the same analysis. The following
antibodies were used: rabbit anti-PDE7A (Santa Cruz Biotech),
goat anti-PDE7B (Santa Cruz Biotech), goat anti-Cox-2 (Santa
Cruz Biotech), goat anti-TNFa (Santa Cruz Biotech), rabbit anti-
Figure 5. Effect of S14 on dopaminergic cell death in vivo. LPS (10 mg) or vehicle was injected unilaterally into the adult substantia nigra pars
compacta (SNpc) of adult rats. A group of animals also received S14 (20 nmol) or BRL50481 (BRL, 60 nmol) together with LPS. After 72 h the brains
were removed and tissue sections were processed for (A) Nissl staining to label neurons or (B) tyrosine hydroxylase (TH) immunoreactivity to label
dopaminergic neurons. Scale bars, 500 mm. Insets scale bars, 100 mm. Quantification of the numbers of neurons in A or TH-immunoreactive (IR) cells
in B is shown. Values represent the mean 6 SD, expressed as a percentage of vehicle-treated animals, from three different experiments, four animals/
experiment/experimental group, and five independent sections per animal.
***p,0.001 versus LPS-treated animals.
doi:10.1371/journal.pone.0017240.g005
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PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e17240Figure 6. Effect of S14 on in vivo inflammation and rotational behavior. Lipopolysaccharide (LPS, 10 mg) or vehicle was injected unilaterally
into the adult substantia nigra pars compacta (SNpc) of adult rats. A group of animals also received S14 (20 nmol) or BRL50481 (BRL, 60 nmol)
together with LPS. (A) After 72 h the brains were removed and tissue sections were processed for CD11b (OX-42) immunoreactivity lo label activated
microglia. Scale bars, 500 mm. Insets scale bars, 100 mm. Quantification of the reactive cells is expressed as the mean 6 SD, from three different
experiments, four animals/experiment/experimental group, and five independent sections per animal.
***p,0.001 versus LPS-treated animals. (B)
Behavioral analysis. Three weeks after treatment apomorphine-induced rotations were analyzed in control, LPS-injected, and LPS+S14-injected rats.
Values represent the means 6 SD from three different experiments.
***p,0.001, versus LPS-injected animals.
doi:10.1371/journal.pone.0017240.g006
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hydroxilase (Sigma) and mouse anti-NeuN (Chemicon). For the
quantification of COX-2, TNF-a and TH immunoreactive cells,
the number of positive cells was quantified in 20 independent
random fields at x400 magnification.
Measurement of apoptosis. To calculate the extend of
apoptotic cell death, SH-SY5Y cells were treated or not with S14,
incubated with 6-OHDA for 16 h, and phosphatydilserine (PS)
exposure on the surface of apoptotic cells was detected by confocal
microscopy after staining with Annexin V-FITC (Bender
MedSystems, Vienna, Austria). Levels of active caspase-3 were
also determined using a specific rabbit anti-active caspase-3
antibody (R&D Systems). For the quantification of Annexin-V-
positive cells and active caspase-3 immunoreactive cells, the
number of positive cells was quantified as described above.
Statistics analysis
Statistical comparisons for significance among differents groups
of animals were performed by ANOVA followed by Newman-
Keuls’test for multiple comparisons. Student’s t-test was used to
analyze statistical differences between cells. Differences were
considered statistically significant at p,0.05.
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